Johnson & Johnson

JNJ: Somewhat-Bearish (-0.214)

Relevance 0.622

24/7 Wall St.•7/13/2026

The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

marketscreener.com•7/13/2026

RBC Raises Price Target on Johnson & Johnson to $287 From $265, Keeps Outperform Rating

Yahoo Finance UK•7/13/2026

Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others

Somewhat-Bullish (0.242)

Villere ST Denis J & Co. LLC Sells 4,470 Shares of Johnson & Johnson $JNJ

Somewhat-Bullish (0.227)

JNJ: Somewhat-Bullish (0.228)

TIKR.com•7/13/2026

PepsiCo Reports Q2 Earnings. Here’s What Stood Out.

PepsiCo's Q2 earnings showed a 6% revenue growth to $24.18 billion, the fastest pace recorded, while operating income grew by 4% to $4.10 billion as gross margin slightly declined. TIKR's model sets a target price of $192 for PepsiCo stock, suggesting a 40% total return. The company's North American turnaround faces headwinds from rising gas prices impacting its beverage division, but international revenue and operating margins are accelerating.

Ramsay Stattman Vela & Price Inc. Cuts Position in Johnson & Johnson $JNJ

Ramsay Stattman Vela & Price Inc. reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 6.6% in the first quarter, selling 4,712 shares but still retaining 66,263 shares valued at $16.2 million. Despite this, institutional ownership remains high at 69.55%, with several other firms increasing their positions. Analysts are largely bullish on J&J, with an average price target of $258.13, following strong earnings and a dividend increase, though a recent $45 million talc-related verdict presents a legal risk.

Neutral (0.002)

JNJ: Neutral (-0.083)

MarketBeat•7/13/2026

Manning & Napier Advisors LLC Lowers Stake in Johnson & Johnson $JNJ

Manning & Napier Advisors LLC reduced its stake in Johnson & Johnson by 11.5% in the first quarter, selling 14,444 shares and retaining 111,439 shares valued at $27.24 million. Despite this, institutional ownership of Johnson & Johnson remains high at 69.55%, with several other firms increasing their positions. The company maintains a "Moderate Buy" consensus from analysts, recently increased its dividend, and reported better-than-expected earnings, though legal risks related to talc allegations persist.

Neutral (-0.106)

JNJ: Neutral (-0.101)

MarketBeat•7/13/2026

Johnson & Johnson $JNJ Shares Sold by Conning Inc.

Conning Inc. reduced its stake in Johnson & Johnson ($JNJ) by 8.5% in the first quarter, selling 13,144 shares. Despite this, Wall Street retains a "Moderate Buy" consensus on J&J, with Bank of America raising its price target to $263, though legal risks related to talc allegations persist after a recent $45 million mesothelioma verdict was affirmed. J&J's stock performance shows a 1-year low of $154.80 and a 1-year high of $269.43, and the company recently increased its quarterly dividend.

Main Street Research LLC Grows Stock Holdings in Johnson & Johnson $JNJ

Main Street Research LLC increased its stake in Johnson & Johnson (JNJ) by 4.2% in the first quarter, bringing its total holdings to 186,882 shares valued at approximately $45.7 million. Wall Street analysts maintain a "Moderate Buy" rating for J&J with an average price target of $258.13, following strong Q1 earnings that beat estimates and a raised quarterly dividend to $1.34 per share. Various other hedge funds have also adjusted their positions in J&J, and the company continues to see analyst support despite recent legal concerns over talc-related asbestos allegations.

Johnson & Johnson $JNJ Shares Bought by Kestra Advisory Services LLC

Kestra Advisory Services LLC increased its stake in Johnson & Johnson (JNJ) by 6.1% in the first quarter, now holding 424,980 shares valued at $103.9 million. While many institutional investors have also adjusted their holdings, JNJ faces positive analyst sentiment with a "Moderate Buy" rating and an average price target of $258.13, alongside ongoing legal risks related to talc litigation despite a strong Q1 earnings beat and a boosted dividend.

Neutral (0.091)

JNJ: Somewhat-Bullish (0.290)

The Globe and Mail•7/12/2026

MarketBeat•7/12/2026

Isthmus Partners LLC Has $19.95 Million Position in Johnson & Johnson $JNJ

Isthmus Partners LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 16.7% in the first quarter, now holding 81,633 shares valued at $19.95 million, making it their 4th largest holding. Other institutional investors also adjusted their positions, and a Johnson & Johnson EVP recently sold 10,000 shares. The company reported strong financial results for Q1 and increased its quarterly dividend.

First Horizon Corp Purchases 14,753 Shares of Johnson & Johnson $JNJ

First Horizon Corp increased its stake in Johnson & Johnson by 10.4% in the first quarter, now holding 156,025 shares valued at approximately $38.1 million. Johnson & Johnson has attracted positive analyst attention, with a "Moderate Buy" consensus rating and an average price target of $258.13, alongside recently raised dividends and better-than-expected earnings. The company faces ongoing legal risks from a $45 million mesothelioma verdict tied to talc-related asbestos allegations.

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

This article compares two ETFs: State Street Health Care Select Sector SPDR ETF (XLV) and Invesco Nasdaq Biotechnology ETF (IBBQ), for investors seeking healthcare exposure. XLV offers broad stability with lower costs and volatility, tracking 60 S&P 500 healthcare stocks, while IBBQ provides concentrated exposure to the biotech subsector with higher historical returns but also higher volatility and expense ratios. The analysis details their respective holdings, expense ratios, dividend yields, performance, and risk metrics to help investors choose based on their risk tolerance and investment goals.

Somewhat-Bullish (0.258)

JNJ: Somewhat-Bullish (0.339)

Relevance 0.609

The Motley Fool•7/11/2026

Which is the Better Choice for Healthcare Investors? IYH or BBH?

This article compares two healthcare-focused ETFs, iShares U.S. Healthcare ETF (IYH) and VanEck Biotech ETF (BBH), for investors. IYH offers broader exposure to the healthcare sector with 100 holdings and lower volatility, while BBH focuses on fewer biotechnology firms, offering higher growth potential but also greater volatility. The analysis details their costs, performance, risk, and core holdings to help investors decide based on their preferences for stability versus growth.

Somewhat-Bullish (0.195)

JNJ: Somewhat-Bullish (0.290)

Relevance 0.693

The Globe and Mail•7/11/2026

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

This article compares two healthcare-focused ETFs: State Street Health Care Select Sector SPDR ETF (XLV) and Invesco Nasdaq Biotechnology ETF (IBBQ). XLV offers broad exposure to the healthcare sector with lower costs and volatility, while IBBQ provides focused exposure to biotechnology with higher historical returns but also higher volatility. The article highlights their differences in expense ratios, holdings, and risk profiles to help investors choose based on their preference for stability versus thematic growth.

Somewhat-Bullish (0.245)

JNJ: Somewhat-Bullish (0.260)

Relevance 0.746

The Globe and Mail•7/11/2026

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

This article compares two healthcare-focused ETFs: the State Street Health Care Select Sector SPDR ETF (XLV) and the Invesco Nasdaq Biotechnology ETF (IBBQ). XLV offers broad, stable exposure to the healthcare sector with lower costs and established megacap holdings, while IBBQ provides concentrated, higher-growth potential in the volatile biotechnology sector. Investors must weigh stability and lower costs against higher historical returns and greater risk when choosing between these funds.

Somewhat-Bullish (0.302)

JNJ: Somewhat-Bullish (0.269)

Relevance 0.728

MarketBeat•7/11/2026

Integrated Advisors Network LLC Has $359,000 Stock Holdings in Sterling Infrastructure, Inc. $STRL

Integrated Advisors Network LLC significantly reduced its stake in Sterling Infrastructure, Inc. (NASDAQ:STRL) by 75.7% in the first quarter, now holding 881 shares valued at $359,000. Despite this, institutional ownership remains high at 80.95%, with major firms like State Street and Invesco holding substantial positions. Sterling Infrastructure posted strong quarterly results, beating EPS and revenue estimates, and analysts maintain a "Buy" consensus with an average price target of $720.67.

Neutral (0.137)

JNJ: Neutral (-0.101)

Relevance 0.635

Quartr•7/11/2026

Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

This article summarizes Protagonist Therapeutics' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. The company is transitioning to a commercial stage, anticipating approval for Rusfertide, and boasts a strong financial position due to product launches and partnerships. Key highlights include the successful launch of Icotyde, the upcoming PDUFA date for Rusfertide, and a robust R&D pipeline focusing on differentiated oral peptides and large-scale partnerships.

Bullish (0.419)

JNJ: Somewhat-Bullish (0.321)

Relevance 0.605

ad-hoc-news.de•7/11/2026

Kenvue stock holds steady as the consumer health story builds

Kenvue stock, trading on the NYSE under ISIN US49177J1025, maintains stability due to its strong consumer health portfolio and well-known household brands. Spun off from Johnson & Johnson, the company's revenue is tied to everyday health products, focusing on brand strength, pricing power, and category resilience. The stock is viewed as a defensive play within the consumer staples and healthcare sectors.

Somewhat-Bullish (0.267)

JNJ: Somewhat-Bullish (0.239)

Relevance 0.714

Kavout | AI•7/11/2026

Why is Johnson & Johnson Selling its Orthopedics Unit

Johnson & Johnson is divesting its DePuy Synthes orthopedics unit, a $9.2 billion business, to focus on higher-growth, higher-margin segments in Innovative Medicine and MedTech. This strategic move aims to transform J&J into a leaner "innovation powerhouse" with improved financial metrics. The standalone DePuy Synthes will become the largest pure-play orthopedics company, potentially driving focused innovation and attracting M&A interest in the over $50 billion global market.

Somewhat-Bullish (0.317)

mergers and acquisitions

JNJ: Bullish (0.425)

Caledonian Record•7/10/2026

Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue

The Illinois Appellate Court has affirmed a $45 million jury verdict against Johnson & Johnson and Kenvue in a mesothelioma case. The verdict was awarded to the family of Theresa Garcia, who developed mesothelioma after using Johnson & Johnson's Baby Powder, which was found to be contaminated with asbestos. This decision is significant as it rejects Johnson & Johnson's attempts to overturn or substantially reduce the judgment and holds Kenvue liable as a successor to Johnson & Johnson's consumer products business.

Bearish (-0.434)

JNJ: Bearish (-0.443)

Relevance 0.990

24/7 Wall St.•7/10/2026

Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner

Johnson & Johnson (JNJ) and AbbVie (ABBV) both reported Q1 2026 earnings, showcasing different strategies for pharma dominance. JNJ delivered a strong quarter with oncology growth and its 64th consecutive dividend hike, appealing to risk-averse income investors. AbbVie, while demonstrating significant revenue growth driven by Skyrizi and Rinvoq, faced an EPS miss due to a pipeline charge, making it more attractive to growth-plus-income buyers willing to tolerate more volatility.

Neutral (0.131)

JNJ: Somewhat-Bullish (0.277)

Relevance 0.979

Investing.com•7/10/2026

Edwards Lifesciences CVP sells $56,762 in company stock

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences Corp (NASDAQ:EW), sold 619 shares of company stock for $56,762 after acquiring them through employee stock options. The transactions were conducted under a Rule 10b5-1 trading plan. Following the sale, Mr. Lippis retains over 40,000 direct shares and nearly 5,000 unexercised stock options.

Somewhat-Bullish (0.198)

JNJ: Somewhat-Bullish (0.234)

Relevance 0.639

www.marketscreener.com•7/10/2026

Clearmind Medicine Submits Formal Response To HHS RFI Highlighting MEAI-Based Candidate CMND-100 For Alcohol Use Disorder And Binge Behaviors

Clearmind Medicine has submitted a formal response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI), advocating for its MEAI-based candidate, CMND-100, as an intervention for alcohol use disorder and binge behaviors. The company highlights CMND-100 as an innovative, non-hallucinogenic neuroplastogen that could offer an inexpensive, scalable, and clinically effective treatment option, particularly appealing because of its low abuse potential and focus on moderation and long-term recovery. This approach emphasizes FDA-regulated research into neuroplastogens that promote neuroplasticity without the hallucinogenic effects and costly supervised dosing typically associated with classic psychedelics.

Somewhat-Bullish (0.239)

Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 7.27% on Jul 10: What Signal Does It Send?

Arrowhead Pharmaceuticals Inc. (ARWR) stock fell by 7.27% on July 10, driven by investor concerns about its late-stage clinical pipeline, intensified competition in RNAi therapeutics, and potential equity dilution. The company reported annual revenue of $829.45 million and a net loss of $1.63 million, with technical indicators showing mixed signals (MACD buy, RSI neutral, Williams %R buy). Analysts have an average price target of $90.90 for ARWR, despite risks like loss of long-term asset value due to a royalty agreement, high operational cash burn, and concentrated clinical risk.

Bearish (-0.421)

JNJ: Somewhat-Bearish (-0.310)

Relevance 0.628

The Globe and Mail•7/10/2026

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?

This article compares two iShares healthcare ETFs, IHE (U.S. Pharmaceuticals) and IBB (Biotechnology), to help investors decide which is a better fit for their portfolio. IHE offers a lower expense ratio, higher dividend yield, and less volatility, focusing on established pharmaceutical companies. IBB provides broader diversification across the biotech landscape and caters to investors seeking higher growth potential with increased risk.

Somewhat-Bullish (0.189)

JNJ: Somewhat-Bullish (0.249)

Relevance 0.609

MarketBeat•7/10/2026

Traders Buy Large Volume of Kenvue Call Options (NYSE:KVUE)

Traders showed significant bullish sentiment towards Kenvue (NYSE:KVUE) by purchasing 12,993 call options, a 144% increase over the average volume. This unusual options activity follows Kenvue's recent solid earnings report, where the company beat analyst estimates for both EPS and revenue. Despite the positive earnings, Wall Street analysts maintain a consensus "Hold" rating for Kenvue with an average price target of $19.33.

Somewhat-Bullish (0.214)

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Jul 10: Facts Behind the Movement

Gilead Sciences Inc (GILD) stock fell by 3.26% on July 10, primarily due to the failure of a Phase 3 solid tumor clinical trial and broader macroeconomic pressures. Strong employment data contributed to increased Treasury yields, negatively impacting biotech valuations. Analysts are expected to lower earnings forecasts, adding to investor uncertainty despite Gilead's strong HIV franchise.

Bearish (-0.357)

JNJ: Somewhat-Bearish (-0.183)

Relevance 0.630

Yahoo Finance•7/10/2026

Otsuka ICU Medical outlays $500m to expand US manufacturing footprint

Otsuka ICU Medical is investing $500 million to expand its US-based IV manufacturing capabilities, including a new 500,000-square-foot facility and upgrades to an existing 700,000-square-foot site in Austin, Texas. This expansion aims to enhance supply reliability for North American customers, especially after disruptions caused by Hurricane Helene in 2024 severely impacted the IV market. The move aligns with a broader trend of life sciences companies strengthening their US manufacturing footprints.

Somewhat-Bullish (0.348)

JNJ: Somewhat-Bullish (0.320)

Relevance 0.601

Trefis•7/10/2026

JNJ Stock Keeps Climbing. Should You Climb On?

Johnson & Johnson (JNJ) stock has surged over 71% in the past year, outperforming the S&P 500, driven by strong operating margins, revenue growth, and a promising pipeline of new drugs like ICOTYDE. However, its premium valuation, evidenced by high P/E and P/S ratios, and some weakness in its MedTech division, particularly the Surgery business, suggest that the current price might already factor in much of its future success. The key for continued growth will be the rapid market adoption and revenue generation from new products to offset challenges like biosimilar competition for established blockbusters like STELARA.

CG Oncology (CGON) Jefferies Global Healthcare Conference 2026 Summary

CG Oncology presented at the Jefferies Global Healthcare Conference 2026, highlighting its lead product, cretostimogene, for non-muscle invasive bladder cancer (NMIBC). The company emphasized the drug's unique mechanism, favorable safety profile with zero Grade 3 adverse events, and strong clinical data, including a 76% complete response rate in BCG-unresponsive CIS, demonstrating superior durability compared to competitors. CG Oncology is targeting a significant market opportunity and expects further data readouts and a potential launch in 2026.

Somewhat-Bullish (0.298)

JNJ: Neutral (0.137)

Relevance 0.643

Fierce Pharma•7/10/2026

Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector

Sanofi has received FDA approval for Sarclisa Escena, a subcutaneous formulation of its multiple myeloma treatment Sarclisa, which can be administered by an on-body injector (OBI). This makes it the first anticancer drug delivered via OBI and aims to boost Sarclisa's competitiveness against Johnson & Johnson's Darzalex, which had previously secured a subcutaneous version. The new formulation significantly reduces administration time and offers similar efficacy and safety to the intravenous version.

Bullish (0.447)

JNJ: Somewhat-Bullish (0.329)

Relevance 0.909

GlobeNewswire•7/10/2026

ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for Erasca, Inc. (NASDAQ: ERAS) investors who purchased shares between January 14, 2025, and April 26, 2026. This alert concerns a securities class action lawsuit alleging that Erasca made materially false and/or misleading statements regarding ERAS-0015's preclinical data, which was

Somewhat-Bearish (-0.237)

finance

JNJ: Neutral (-0.133)

Relevance 0.591

Reuters•7/10/2026

US FDA approves Sanofi's wearable injector form of blood cancer drug

The U.S. FDA has approved a wearable injector form of Sanofi's blood cancer drug, Sarclisa, for patients with multiple myeloma. This marks the first cancer drug approved by the FDA for delivery via an on-body injector, significantly reducing treatment time for patients compared to traditional intravenous infusions. The approval is a boost for Sanofi, which aims to diversify its portfolio beyond its top-selling asthma drug, Dupixent.

Somewhat-Bullish (0.174)

JNJ: Neutral (-0.139)

Relevance 0.722

Ad Hoc News•7/10/2026

Merck & Co. stock holds steady as a big pharma mainstay in the S&P 500

Merck & Co. stock (MRK) stands as a major pharmaceutical presence in the S&P 500, offering a diversified portfolio of oncology and vaccine products that drive long-term earnings. The company balances innovation with patent expiry challenges, investing heavily in R&D and strategic acquisitions to maintain its market position. Its role in global health and consistent dividend payments make it an attractive holding for investors seeking defensive characteristics and exposure to medical innovation.

Bullish (0.354)

JNJ: Somewhat-Bullish (0.341)

Relevance 0.577

Modern Healthcare•7/10/2026

Inside medtech’s cameo run on HBO Max’s ‘The Pitt’

The article highlights the appearance of medical technology devices from companies like Philips and Stryker, as well as Butterfly Network Inc.'s Butterfly iQ3 ultrasound device, in the HBO Max series "The Pitt." It focuses on the presence of these medtech products within a popular television show. The article itself is brief, primarily serving as an introduction to this observation.

Indianapolis Business Journal•7/10/2026

Indiana man’s widow to take Johnson & Johnson to trial in Marion County over asbestos exposure

The widow of an Indiana man is preparing to take Johnson & Johnson to trial in Marion County over alleged asbestos exposure. This legal action follows recent news of other significant lawsuits, including an Ohio judge granting a preliminary injunction in an NCAA eligibility case and New York suing 3M, DuPont, and Corteva over "forever chemicals." The trial highlights ongoing litigation surrounding corporate responsibility and environmental/public health impacts.

Bearish (-0.711)

JNJ: Bearish (-0.709)

Simply Wall Street•7/9/2026

Johnson & Johnson (JNJ) Wins FDA Nod For Dual Energy Heart Rhythm Catheter

Johnson & Johnson (JNJ) has received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a catheter ablation system for treating atrial fibrillation and other arrhythmias. This approval diversifies J&J's MedTech offerings beyond pharmaceuticals and consumer products, with the company trading positively supported by analyst targets and a an undervalued stock flag. Investors are now focused on its commercialization, adoption trends, and impact on J&J's overall MedTech segment.

Yahoo Finance•7/9/2026

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?

This article compares the Invesco Pharmaceuticals ETF (PJP) and the State Street SPDR S&P Biotech ETF (XBI) for investors seeking healthcare exposure. PJP offers a less volatile, concentrated pharmaceutical focus with a higher dividend yield, while XBI provides high-growth, equal-weighted biotechnology exposure at a lower cost, featuring significant small-cap stock representation. The article concludes that XBI is the better buy due to its long-term performance, despite its higher volatility and past maximum drawdown.

Somewhat-Bullish (0.197)

JNJ: Neutral (0.132)

Relevance 0.627

Barchart.com•7/9/2026

Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen

The Degenerative Disc Disease (DDD) market is projected to grow significantly from $1.2 billion in 2025 to $7.2 billion by 2036, driven by advancements in regenerative therapies and rising prevalence. Key companies like Mesoblast and BioRestorative Therapies are making progress in clinical trials, with potential FDA approvals and market expansions anticipated. The market growth is fueled by an aging population and innovations in minimally invasive treatments, despite challenges like high costs and diagnostic complexities.

Somewhat-Bullish (0.292)

JNJ: Somewhat-Bullish (0.215)

Relevance 0.585

MedTech Dive•7/9/2026

J&J wins FDA approval for dual-energy ablation catheter

Johnson & Johnson has received FDA approval for its Dual Energy Thermocool Smarttouch SF Platform, a catheter that can deliver both radiofrequency and pulsed field energy for treating atrial fibrillation. This new dual-energy device, which was previously CE marked in January 2025, is expected to begin U.S. procedures this summer and will help J&J regain market share in the electrophysiology space against competitors like Boston Scientific and Medtronic. The catheter's versatility, allowing physicians to toggle between energy types, is particularly valuable for complex procedures.

Somewhat-Bullish (0.280)

R&D Tax Credits: Fueling Innovation in Technology & Life Sciences

Research and development (R&D) tax credits are a crucial strategic tool for growth and innovation, particularly within the technology and life sciences sectors. These credits offer significant financial benefits, including federal income tax reductions, AMT offsets, and payroll tax offsets for startups, with potential carryforward benefits for up to 20 years. Recent legislative changes, such as the One Big Beautiful Bill Act (OBBBA), further enhance these incentives through immediate expensing of domestic R&D costs, underscoring the importance of a well-documented approach to leverage these benefits effectively.

Bullish (0.366)

technology

JNJ: Somewhat-Bullish (0.305)

Relevance 0.645

citybiz•7/9/2026

KKR Launchs Allyntra to Build Precision Manufacturing Platform for Medtech Industry

KKR has launched Allyntra, a new precision-engineered solutions platform, to serve the medical technology and high-precision industrial markets. This initiative builds on KKR's existing investment in Precipart and aims to expand through acquisitions, innovation, and commercial growth. Allyntra will focus on advanced surgical applications and is led by CEO Robbie Atkinson and Chairman Brian Highley, who bring extensive experience in scaling manufacturing organizations in the medtech sector.

Somewhat-Bullish (0.292)

mergers and acquisitions

JNJ: Somewhat-Bullish (0.265)

Relevance 0.609

Yahoo•7/9/2026

Johnson & Johnson’s DE STSF platform secures FDA approval

Johnson & Johnson has received FDA approval for its Dual Energy Thermocool Smarttouch SF Platform (DE STSF) for catheter ablation. This platform enables physicians to use both radiofrequency (RF) and pulsed field (PF) energy through a single catheter, integrated with the CARTO ecosystem for precise energy delivery. J&J plans a phased commercial rollout in the US later this year, following a successful launch in Europe.

Medical Device Network•7/9/2026

Johnson & Johnson’s DE STSF platform secures FDA approval

Johnson & Johnson has received FDA approval for its Dual Energy Thermocool Smarttouch SF Platform (DE STSF), a system designed to assist electrophysiologists in catheter ablation procedures. This platform integrates both radiofrequency (RF) and pulsed field (PF) energy delivery within a single catheter, building on existing technology. The DE STSF platform is integrated with the CARTO ecosystem, offering advanced mapping, imaging, and PF Index guidance, with a phased commercial rollout expected later this year in the US.

Ad-hoc-news.de•7/9/2026

Haleon plc balances branded consumer health growth with portfolio streamlining

Haleon plc is strategically refining its consumer health portfolio, prioritizing key brands in oral care, pain relief, respiratory, and vitamins while managing its post-spin-off legacy from GSK and Pfizer. The company focuses on steady cash generation, disciplined capital allocation, and operational resilience, investing in organic growth and targeted acquisitions. Its innovation strategy involves incremental, consumer-led improvements across a diversified brand portfolio, aiming for sustained relevance in a competitive market.

Somewhat-Bullish (0.229)

JNJ: Neutral (0.107)

Relevance 0.553

ETF Database•7/9/2026

Strong LLY News Boosts Active Healthcare ETF GDOC

The active healthcare ETF GDOC received a boost from positive news surrounding its largest holding, Eli Lilly (LLY). JPMorgan raised its price target for Eli Lilly, contributing to GDOC's recent 11.8% return over three months. The ETF, which actively invests in companies driving innovation in healthcare, is well-positioned for a strong second half, potentially benefiting from future interest rate cuts and increased M&A activity.

Bullish (0.413)

JNJ: Somewhat-Bullish (0.345)

Relevance 0.700

Simply Wall Street•7/9/2026

Positive IgA Nephropathy Data And Yen Loan Recast Could Be A Game Changer For Viatris (VTRS)

Viatris (VTRS) recently secured a refinanced JPY 40 billion term loan and reported positive Phase 3 results for VR-205 (Nefecon) in Japanese adults with IgA nephropathy. These developments support the company's shift towards higher-value specialty therapies and could act as a catalyst for future growth, despite ongoing pressures in its generics portfolio. Analysts project significant revenue and earnings growth for Viatris by 2029.

Somewhat-Bullish (0.236)